Conferences

IAS 2017

The 9th IAS Conference on HIV Science (IAS 2017), organised by the International AIDS Society, took place in Paris, France, from 23-26 July 2017.
Undetectable viral load & treatment as prevention

International study of gay couples reports no transmissions from an HIV-positive partner on treatment

The search for a cure

Why curing HIV may be like curing cancer – and may be as difficult

PrEP science

Experts concur that event-related oral PrEP probably won’t work for women

Transgender people

Who are trans women acquiring HIV from?

PrEP programmes & uptake

One in seven people offered PrEP in African study start it immediately

Drug interactions & pharmacokinetics

Trans women wary of antiretroviral drug and hormone interactions

Health problems & ageing

People with HIV are at risk for liver fibrosis and steatosis

Cardiovascular disease

Peripheral artery disease more common in people with HIV with lower CD4 counts

PrEP programmes & uptake

PrEP use in US exceeds 100,000 in Gilead pharmacy survey

Changing treatment

Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease

New & experimental HIV treatments

Boosted darunavir plus lamivudine matches three-drug regimen

The search for a cure

What marks out HIV controllers from others?

The search for a cure

Can we achieve a complete HIV cure in more patients?

The search for a cure

VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment

New & experimental HIV treatments

Long-acting NRTI shows promise for HIV treatment and PrEP

Child developmental issues

Stillbirth more frequent in women with HIV in UK and Ireland than in general population

Finance & funding

US HIV funding decisions on PEPFAR in 2017 will have critical effect on ability to reach 90-90-90 goals

New & experimental HIV treatments

First protease inhibitor combination pill maintains viral suppression

Pregnancy and vertical transmission

Adolescents with HIV do better in more prosperous African countries, even with treatment

PrEP

France’s next PrEP study aims to assess the wider impact of PrEP on the HIV epidemic

PrEP programmes & uptake

Dutch study finds out whether gay men prefer daily or on-demand PrEP

Injectable & long-acting PrEP

Long-acting cabotegravir injection shows promise for HIV prevention

New & experimental HIV treatments

Doravirine combination pill looks good for initial HIV treatment

Side effects

Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

Access to healthcare

Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows

Circumcision

Medical male circumcision for HIV has benefits for women too

PrEP

Demonstration projects explore the feasibility of PrEP for adolescents and young women in South Africa

PrEP science

Ipergay trial: PrEP still protected people who had less sex and used it less often

The search for an HIV prevention vaccine

Another HIV vaccine efficacy trial will start this year

New & experimental hepatitis C treatment

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

Global health targets

90-90-90 progress in southern Africa: HIV testing gap needs to be closed in young people and men

Self-testing & home testing

Can self-testing engage 'hard-to-reach' men with HIV testing?

Treatment for women

Integrase inhibitors not causing higher rates of adverse birth outcomes, Botswana and French studies show

Starting treatment

New guidance says start HIV treatment within 7 days of diagnosis – but is everyone ready?

New & experimental HIV treatments

New integrase inhibitor bictegravir works well for first-line HIV treatment

Hepatitis C treatment

Hepatitis C treatment is effective and feasible in Africa

Self-testing & home testing

High uptake of HIV self-testing by female sex workers in African countries

The search for a cure

South African child has controlled HIV off treatment for 8.5 years

Self-testing & home testing

Programme to provide free self-tests helps gay men to test for HIV more often

Improving HIV care

Less frequent clinic visits for HIV care: fine tuning needed

Opportunistic infections

Improved treatment for cryptococcal meningitis in HIV could save thousands of lives – if generic drug becomes available

Undetectable viral load & treatment as prevention

Swaziland: new infections halved in five years as HIV treatment scales up

New & experimental HIV treatments

Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks

PrEP programmes & uptake

London gonorrhoea rates fall, and HIV rates falling in Australia as more join PrEP demo

Global health targets

World on track to reach the 90-90-90 targets for HIV treatment by 2020

Opportunistic infections

WHO recommends package of tests, treatment and prevention for 'urgent need' people with HIV with low CD4 counts

Videos

IAS 2017: HIV Community Forum

23 August 2017

Our HIV Community Forum shared information on HIV treatment and prevention from the 9th IAS Conference on HIV Science. With Dr Tristan Barber, from Chelsea and Westminster NHS Foundation Trust; Memory Sachikonye, from UK Community Advisory Board (UK-CAB); and Gus Cairns and Roger Pebody, from NAM aidsmap.